<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancerToshiyuki Hirano, Kenzo Soejima, Hiroyuki Yasuda et al.|Oncotarget|2015Cited by 159
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung CancerMasayoshi Miyawaki, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Research|2016Cited by 73
Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer CellsTetsuo Tani, Kenzo Soejima, Hiroyuki Yasuda et al.|Molecular Cancer Therapeutics|2015Cited by 63
Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancerKeiko Ohgino, Tomoko Betsuyaku, Kenzo Soejima et al.|Lung Cancer|2013Cited by 49
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung CancerKota Ishioka, Koichi Fukunaga, Hiroyuki Yasuda et al.|Cancer Research|2021Cited by 43